Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620937 | 0.96 | CA1 (0.43) | CA1CA2CA4 | |
| SCHEMBL28886067 | 0.86 | CYP1A2 (0.38) | CA1CA2CA4CYP1A2 | |
| SCHEMBL2288404 | 0.82 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL19592339 | 0.82 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL2263208 | 0.82 | EPHX1 (0.34) | CA1CA2CA4CYP1A2 | |
| SCHEMBL2261801 | 0.80 | EPHX1 (0.37) | CA1CA2CA4CYP1A2 | |
| SCHEMBL20380947 | 0.80 | CA1 (0.31) | CA1CA2CA4 | |
| SCHEMBL24929562 | 0.77 | — | — | |
| SCHEMBL24929113 | 0.77 | — | — | |
| SCHEMBL24404223 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814722-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2217563-B1 | Alpha-substituted cyclopentanecarbonitriles or cyclohexanecarbonitriles and their use in perfumery | FIRMENICH & CIE (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-8003084-B2 | α-substituted cyclopentanecarbonitriles or cyclohexanecarbonitriles and their use in perfumery | FIRMENICH SA (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20100247467-A1 | ALPHA-SUBSTITUTED CYCLOPENTANECARBONITRILES OR CYCLOHEXANECARBONITRILES AND THEIR USE IN PERFUMERY | FIRMENICH SA (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2217563-A2 | ALPHA-SUBSTITUTED CYCLOPENTANECARBONITRILES OR CYCLOHEXANECARBONITRILES AND THEIR USE IN PERFUMERY | Firmenich S.A. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060378-A2 | ALPHA-SUBSTITUTED CYCLOPENTANECARBONITRILES OR CYCLOHEXANECARBONITRILES AND THEIR USE IN PERFUMERY | FIRMENICH SA (CH) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247467-A1 | ALPHA-SUBSTITUTED CYCLOPENTANECARBONITRILES OR CYCLOHEXANECARBONITRILES AND THEIR USE IN PERFUMERY | PNN, FASN, CYP8B1 | CA1 2439/4885CA2 2591/4885CA4 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.